Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 785

1.

Transplantation as salvage therapy for high-risk patients with myeloma in relapse.

Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G.

Bone Marrow Transplant. 2002 Dec;30(12):873-8.

PMID:
12476279
[PubMed - indexed for MEDLINE]
Free Article
2.

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G.

Exp Hematol. 2003 Jan;31(1):73-80.

PMID:
12543109
[PubMed - indexed for MEDLINE]
3.

Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.

Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali S, Amaddii G, Coser P, Tribalto M, Raimondi R, Bergonzi C, Sajeva MR, Sica S, Ferrando F, Messina G, Mandelli F.

Haematologica. 1999 Sep;84(9):844-52.

PMID:
10477460
[PubMed - indexed for MEDLINE]
Free Article
4.

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.

PMID:
19285634
[PubMed - indexed for MEDLINE]
5.

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T.

Hematol J. 2002;3(4):185-92.

PMID:
12189564
[PubMed - indexed for MEDLINE]
6.

High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.

Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.

Natl Med J India. 2003 Jan-Feb;16(1):16-21.

PMID:
12715951
[PubMed - indexed for MEDLINE]
7.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR.

Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708.

PMID:
15389436
[PubMed - indexed for MEDLINE]
8.

'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.

Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.

Bone Marrow Transplant. 2002 Dec;30(12):885-91.

PMID:
12476281
[PubMed - indexed for MEDLINE]
Free Article
9.

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma.

Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF, et al.

Blood. 1995 Jun 1;85(11):3077-85.

PMID:
7756641
[PubMed - indexed for MEDLINE]
Free Article
10.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.

PMID:
9864146
[PubMed - indexed for MEDLINE]
Free Article
11.

Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.

Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, Bregante S, Raiola AM, di Grazia C, Dominietto A, Tedone E, Piaggio G, Podesta M, Bruno B, Oneto R, Lombardi A, Frassoni F, Rolla D, Rollandi G, Viscoli C, Ferro C, Garbarino L, Van Lint MT.

Haematologica. 2004 Oct;89(10):1238-47.

PMID:
15477210
[PubMed - indexed for MEDLINE]
Free Article
12.

[Intensive treatment of multiple myeloma].

Harousseau JL.

Bull Acad Natl Med. 2003;187(2):405-13; discussion 413-5. Review. French.

PMID:
14556449
[PubMed - indexed for MEDLINE]
13.

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.

Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA.

Cancer. 2006 Mar 1;106(5):1084-9.

PMID:
16456814
[PubMed - indexed for MEDLINE]
Free Article
14.

Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.

Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo F, Ciccone G, Boccadoro M.

Eur J Haematol. 2005 Nov;75(5):391-5.

PMID:
16191088
[PubMed - indexed for MEDLINE]
15.

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.

Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF.

J Clin Oncol. 2008 Dec 10;26(35):5775-82. doi: 10.1200/JCO.2008.17.9721. Epub 2008 Nov 10.

PMID:
19001321
[PubMed - indexed for MEDLINE]
Free Article
16.

High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.

Stein RS, Greer JP, Goodman S, Kallianpur A, Ahmed MS, Wolff SN.

Bone Marrow Transplant. 1999 Feb;23(3):227-33.

PMID:
10084253
[PubMed - indexed for MEDLINE]
Free Article
17.

High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.

Leuk Lymphoma. 2006 Aug;47(8):1545-52.

PMID:
16966265
[PubMed - indexed for MEDLINE]
18.

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P.

Bone Marrow Transplant. 1997 Jul;20(1):21-6.

PMID:
9232251
[PubMed - indexed for MEDLINE]
Free Article
19.

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.

Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S.

Bone Marrow Transplant. 2001 Apr;27(8):821-8.

PMID:
11477439
[PubMed - indexed for MEDLINE]
Free Article
20.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90. Epub 2003 Aug 19.

PMID:
12928754
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk